Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib.

Anticancer research - 1 Jun 2014

Fiala Ondrej, Pesek Milos, Finek Jindrich, Benesova Lucie, Minarik Marek, Bortlicek Zbynek, Topolcan Ondrej

Abstract excerpt

BACKGROUND: Tumor biomarkers are used for predicting therapy effect and prognosis of patients with non-small cell lung cancer (NSCLC). We focused on their potential role in prediction of the efficacy of erlotinib. PATIENTS AND METHODS: In a total of 144 patients with advanced-stage (IIIB or IV) NSCLC treated with erlotinib, pre-treatment levels of soluble carcinoembryonic antigen (CEA) and cytokeratin markers in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to Carcinoembryonic Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Squamous Cell

Share to Erlotinib Hydrochloride

Share to Keratin-19

Share to Neoplasm Staging

Share to Quinazolines

Share to Survival Rate

Source

Identifiers

PMID: 24922695

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib.PMID 24922695Read ↗

Prognostic and predictive value of carcinoembryonic antigen and cytokeratin-19 fragments levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib.Semantic proximity Read ↗

Predictive and Prognostic Value of CYFRA 21-1 for Advanced Non-small Cell Lung Cancer Treated with EGFR-TKIs.Semantic proximity Read ↗

Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.Semantic proximity Read ↗

[Value of carcinoembryonic antigen levels in predicting the efficacy of EGFR-TKI in advanced non-small cell lung cancer harboring EGFR mutations].Semantic proximity Read ↗

[Serum CYFRA21-1 is Correlated with the Efficacy of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor in Non-small Cell Lung Cancer Patients Harboring EGFR Mutations].Semantic proximity Read ↗

Predictive and prognostic value of preoperative serum tumor markers is EGFR mutation-specific in resectable non-small-cell lung cancer.Semantic proximity Read ↗

Distinction of ALK fusion gene- and EGFR mutation-positive lung cancer with tumor markers.Semantic proximity Read ↗

Prognostic value of CYFRA 21 - 1 and Ki67 in advanced NSCLC patients with wild-type EGFR.Semantic proximity Read ↗

Serum carcinoembryonic antigen levels predicts the efficacy of EGFR-TKI in non-small cell lung cancer harboring EGFR mutations.Semantic proximity Read ↗

The Prognostic and Predictive Value of Pretreatment Serum Tumor Markers in Lung Adenocarcinoma with Different EGFR StatusSemantic proximity Read ↗

CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients.Semantic proximity Read ↗

Correlation between EGFR mutations and serum tumor markers in lung adenocarcinoma patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.